Aptorum Shares Are Trading Higher On Immunomodulators Agreement For Autoimmune, Oncology Indications

Aptorum Group Ltd APM has entered into a material transfer and option agreement with Yale University to evaluate a group of preclinical stage novel immunomodulators.
Aptorum also obtained an exclusive option to in-license the novel immunomodulators and related intellectual property rights, including patent rights and know-how, based on licensing terms according to a binding term sheet incorporated into the Agreement.
Under the arrangement, Aptorum will be responsible for assessing Yale's originally developed novel immunomodulators against lupus, arthritis, inflammatory bowel diseases, neurodegenerative diseases, or other oncology indications.
Upon exercising its option to license, Aptorum will develop and commercialize one or more of these novel immunomodulators, as supported by Yale.
Price Action: APM shares are up 4.9% at $2.59 in the premarket session on the last check Thursday.